• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Corcept Therapeutics

Corcept Therapeutics

Corcept Therapeutics Inc CORT

Last Price$5.84Day Change (%)-0.68%
Open Price$5.85Day Change ($)-0.04
Day Range5.74–5.9352-Week Range1.84–6.65

As of Fri 5/22/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Research and Markets: Global Pituitary ACTH Hypersecretion (Cushing's Disease) Pipeline Report 2015 - 9 Companies & 16 Drug Profiles

    Research and Markets: Global Pituitary ACTH Hypersecretion (Cushing's Disease) Pipeline Report 2015 - 9 Companies & 16 Drug Profiles

  2. Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

    Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

  3. Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly

    Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly

  4. A Young Power Couple's Kickstart Portfolio

    With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.

  5. Even in Face of Difficulty, Berkshire Impresses

    Berkshire's non-insurance operations continue to be an added source of stability while reinsurance operations continue to struggle.

  6. Investment Losses Overshadow Berkshire's Third-Quarter Results

    Wide-moat Berkshire Hathaway saw solid top-line results from each of its main segments, but losses from investments, derivatives, and eliminations sent earnings lower.

  7. Berkshire's Second-Quarter Results on Target

    Noninsurance operations continue to be a source of stability, while its insurance business overall may see more meager results during the next couple of years.

  8. Berkshire Starts Out 2014 on a Weaker Note

    Just about every segment at Berkshire was dealing with elevated costs during the first quarter.

  9. Why Berkshire's Moat Isn't Going Away Anytime Soon

    Morningstar's Gregg Warren says Berkshire's sterling balance sheet, strong business, and unique structure will sustain the firm's competitive standing--even without Buffett.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.